Brean Lifts PT on Inovio Pharma (INO) to $5; Expects Strong Data from VGX-3100 Phase 2
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Inovio Pharmaceuticals (INO) Price Target Lifted to $6 at Maxim Group
March 18, 2014 7:12 AM EDTMaxim Group analyst Jason Kolbert reiterated a Buy rating on Inovio Pharmaceuticals (NYSE: INO) and doubled his price target from $3 to $6 following fourth quarter results, saying the best is still ahead.
Kolbert notes the company has plenty of capital runway for... More
Inovio Pharma (INO) Posts Q4 Loss of 4c/Share; Offers Corp. Update
March 17, 2014 6:06 AM EDTInovio Pharmaceuticals, Inc. (AMEX: INO) reported Q4 EPS of ($0.04), $0.01 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $1.7 million versus the consensus estimate of $1.36 million.
orporate Update
Corporate Development
In a major corporate development for the Company, Roche and Inovio entered into an exclusive worldwide license agreement to research, develop and commercialize Inovio's highly-optimized, multi-antigen DNA vaccine products targeting prostate cancer and hepatitis B. Roche licensed Inovio's therapeutic vaccines INO-5150 for prostate cancer and INO-1800 for hepatitis B as well as the use of Inovio's CELLECTRA®... More
